Digestive System Tumours is the first volume in the fifth edition of the WHO series on the classification of human tumors. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumors and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education.
Since a number of mucosal digestive tract cancer detected has increased in recent years with an advance of endoscopic instruments, endoscopic treatment of digestive tract cancer is widely spread in Japan but not in other countries. Minute cancers seem to have own characteristic mucosal signs compared with benign lesions. Therefore, strategies, those are different in Japan from other countries, of endoscopic diagnosis are very important. The cancer institute hospital of JFCR (Japan foundation of cancer research) is one of the top institutions which do the best endoscopic treatment in Japan. This book is expected to be the first valuable atlas in which the abundant experiences of this hospital offer beautiful photographs of minute cancers without any scars of biopsies which change aspects of original lesions. This book also offer pictures of magnifying endoscopy using NBI (Narrow Band Imaging) and pathological findings.
Handbook of Gastrointestinal Cancers is a practical guide to the management of colorectal, pancreatic, hepatocellular, gastric, and esophageal cancers as well as other cancers of the upper and lower gastrointestinal tract. Edited by a multidisciplinary group of oncologists from leading institutions, this book is an essential day-to-day reference for evidence-based treatment and patient care. The handbook focuses on treatment strategies and approaches to cancerous gastrointestinal tumors that are transforming the recent oncological landscape, including expert-given guidance on methods such as neoadjuvant and adjuvant chemotherapy, surgical transplant, radiation therapy, molecular diagnostic testing leading to molecularly targeted therapy, and immunotherapy. With so many advances in the current field, it is increasingly difficult for early-career practitioners to grasp the entirety of practices and for seasoned oncologists to keep up with newly approved therapies, side effects to treatments, and special clinical management considerations, but this handbook addresses it all. Organized by major gastrointestinal disease sites and featuring “How I Treat” case vignettes from world experts for common and uncommon management considerations, the handbook brings an experience-based perspective to these tough-to-treat areas. The treatment strategies and applications set forth in the chapters are pertinent to situations and decision-making encountered in practice. Handbook of Gastrointestinal Cancers is a valuable resource for medical oncologists, radiation oncologists, and surgeons treating and managing gastrointestinal cancers as well as trainees in medical, radiation, and surgical oncology programs needing an accessible point of care resource. KEY FEATURES: Provides treatment plans and recommendations for each stage of a range of gastrointestinal cancers, including colorectal, pancreatic, and hepatocellular cancers plus more Includes “How I Treat” patient vignettes told from the physician’s point of view within each clinical chapter Outlines special considerations for the elderly and for survivors of gastrointestinal cancers Highlights important clinical guidance on nutritional and palliative concerns commonly seen in patients with gastrointestinal cancers
This book is a full colour, highly clinical multi-media atlas focusing on the role diagnostic and therapeutic endoscopy plays in the management of patients with cancer. Conveniently split into sections for each part of the GI tract, each section will follow a consistent structure. With 400 high-quality images and in addition, 21 high-definition videos showing endoscopy from the experts, this book is the perfect consultation and learning tool for all gastroenterologists, endoscopists, GI surgeons and oncologists.
Endoscopy in Early Gastrointestinal Cancers, Volume 1: Diagnosis provides detailed information of the technique of novel endoscopic diagnostic tools including magnifying endoscopy, narrow band imaging system (NBI), autofluorescence endoscopy (AFI), endocytoscopy, FICE and confocal endomicroscopy. Carcinoma of the gastrointestinal tract remained a major health issue worldwide, which is, however notoriously difficult to treat. One of the major reasons for such a poor result is that these cancers are diagnosed at advanced stage. There is a recent increase in the number of gastrointestinal cancers diagnosed at early stage. This is attributed to an increasing recognition of these early stage cancers through a recent development in the technology of endoscopy. This book on the endoscopic diagnosis of early GI neoplasia, containing lots of illustrations, artwork and numerous short video clips, serves as a bridge between the recent development in endoscopy and the knowledge of gastroenterologist, endoscopist and surgeons.
Included here is a discussion of the pathophysiological aspects and risks of laparoscopic staging (such as trocar metastases) on the basis of international experience.
This textbook discusses core principles and practices in gastrointestinal oncology and covers a wide range of practice areas such as pathology and radiologic images, epidemiology, genetics, staging, multidisciplinary management of specific gastrointestinal cancer, and pathology for each primary tumor site. The comprehensive coverage makes Textbook of Gastrointestinal Oncology a useful resource for the practitioner wishing to gain a greater understanding of the principles of managing malignant gastrointestinal disease, as well as medical oncology fellows, surgeons, radiation oncologists, gastroenterologists and fellows, and residents.
This book highlights the importance of understanding gastric and colon cancer metabolism in guiding diagnosis and drug discovery. It summarizes the correlation between adiponectin and matrix metalloproteinase with colorectal cancer. The book also evaluates the divergent role of hypoxia-inducible factor 1 in colorectal cancer growth and metastasis. After discussing the role of genetic polymorphisms in alcohol metabolizing enzymes and EPHX1 with the onset of colorectal cancer, it reviews the molecular mechanisms of chemoresistance in gastric cancer and novel therapeutic strategies to reverse the chemoresistance of tumors. In addition, the book explores the theranostic role of nanoparticles and therapeutic potential of phytochemicals with regard to colorectal cancer. Given its scope, the book offers a valuable guide for oncologists, academic researchers, pharmaceuticals practitioners, and students who are involved in research and treatment of cancer.
Gastrointestinal Malignancies Gastrointestinal (GI) cancers are common diseases worldwide. About 400,000 patients are diagnosed with esophageal cancer worldwide each year and nearly 330,000 die for this disease. Roughly 870,000 patients are newly diagnosed each year with gastric cancer and over 600,000 die from the disease each year. And 940,000 new cases of colorectal cancer are diagnosed annually and 490,000 patients die from this disease. Management options for patients with GI cancer have undergone dramatic changes in the past decade. New cytotoxic agents, novel targeted agents, surgical and ablative options, as well as a new array of supportative medications have shown substantial progress. With the increased number of therapeutic options from which to choose, the clinician is better placed to offer effective therapy. At the same time the clinician is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the options for treatment today and in the future. Gastrointestinal Malignancies provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers evidence-based recommendations. The editors and authors are leaders in their fields. The chapters update the current screening tools for colon cancers, assessment of predictive markers such as k-Ras and BRAF in the management of colon cancer as well as the state-of-the-art for use of both cytotoxic chemotherapy and the incorporation of newer biological therapies. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of the Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advancs in clinical and translational research developments as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice
Gastric cancer has been one of the great malignant scourges affecting man kind for as long as medical records have been kept. Until operative resection pioneered by Bilroth and others became available, no effective treatment was feasible and death from cancer was virtually inevitable. Even with resection by total gastrectomy, the chances of tumor eradication remained small. Over recent years, however, the situation has been changing. Some changes have resulted from better understanding of the disease, early detec tion, and better management techniques with applied clinical research, but the reasons for other changes are poorly understood. For example, the incidence of gastric cancer is decreasing, especially in westernized societies, where it has fallen from one of the most common cancers to no longer being in the top five causes of cancer death. Still it remains the number one killer of adult males in Japan and Korea. Whether the reduced incidence in western societies is a result of dietary changes or methods of food preservation, or some other reason, is as yet uncertain. Improvements in outcome have been reported from mass screening and early detection; more refined techniques of establishing early diagnosis, tumor type, and tumor extent; more radical surgical resection; and resection at earlier stages of disease.
